AUTHOR=Guo Yanjing , Wu Jingjing , Bai Qianming , Wan Juefeng , Wang Qifeng , He Xinhong , Zhang Xiaowei , Luo Zhiguo , Xing Liju , Liu Xin 

TITLE=Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1537714

DOI=10.3389/fonc.2025.1537714

ISSN=2234-943X

ABSTRACT=We present the first case of a male patient with an epidermal growth factor receptor (EGFR) 19del mutation who was diagnosed with intra-abdominal aggressive fibromatosis and familial adenomatous polyposis. We assessed the clinical response of the patient to first-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). A remarkable sustained partial response was achieved with the application of gefitinib after progression on multiple lines of therapy. The main adverse event of gefitinib treatment in this patient was a grade 2 rash. (Funded by the National Natural Science Foundation of China [Grant No. 82003061] and the Shanghai Sailing Program [20YF1408800] to Yanjing Guo, the Natural Science Foundation of Shanghai [Grant No. 24ZR1412800] to Xin Liu).